or
forgot password

    • cancer clinical trials in boston, MA

    • Hydroxychloroquine, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
    Massachusetts General Hospital
    Boston, Massachusetts 02114-2617
    Brain and Central Nervous System Tumors
    Vaccination for the Treatment of Previously Untreated or Relapsed Follicular Lymphoma
    Dana-Farber Cancer Institute
    Boston, Massachusetts 02115
    Follicular Lymphoma
    Procurement of Follicular B Cell Lymphoma Cells for the Purpose of Possible Use in Future Clinical Trials
    Dana-Farber Cancer Institute
    Boston, Massachusetts 02115
    Non-Hodgkin's Lymphoma
    Intermittent Chemotherapy With or Without GM-CSF for Metastatic HPRC
    Dana Farber Cancer Institute
    Boston, Massachusetts 02115
    Prostate Cancer
    S0521, Combination Chemotherapy With or Without Gemtuzumab Followed By Tretinoin, Mercaptopurine, and Methotrexate or Observation in Treating Patients With Acute Promyelocytic Leukemia
    Beth Israel Deaconess Medical Center

    Trial Locations
    Beth Israel Deaconess Medical Center
    Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
    Massachusetts General Hospital
    Leukemia
    ZD6474 (Zactima) and Metronomic Chemotherapy in Advanced Breast Cancer
    Dana-Farber Cancer Institute

    Trial Locations
    Dana-Farber Cancer Institute
    Massachusetts General Hospital
    Metastatic Breast Cancer
    Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma
    Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute

    Trial Locations
    Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute
    Massachusetts General Hospital
    Neuroblastoma
    Efficacy and Safety of Everolimus (RAD001) Compared to Placebo in Patients With Advanced Neuroendocrine Tumors
    Boston Medical Center BMC
    Boston, Massachusetts 02118
    Advanced Neuroendocrine Tumors
    Panitumumab Chemoradiotherapy Chemotherapy for Squamous Cancer of the Head and Neck
    Dana-Farber Cancer Institute

    Trial Locations
    Dana-Farber Cancer Institute
    Massachusetts General Hospital
    Squamous Cell Carcinoma of the Head and Neck
    Early or Delayed Fludarabine and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia
    Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute

    Trial Locations
    Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
    Massachusetts General Hospital
    Dana-Farber/Brigham and Women's Cancer Center
    Leukemia
    RAD001 in Advanced Hepatocellular Carcinoma
    Massachusetts General Hospital
    Boston, Massachusetts 02114-2617
    Hepatocellular Carcinoma
    Avastin and Erlotinib as First Line Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Cancer, and Papillary Serous Mullerian Tumors
    Beth Israel Deaconess Medical Center

    Trial Locations
    Beth Israel Deaconess Medical Center
    Dana-Farber Cancer Institute
    Massachusetts General Hospital
    Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Papillary Serous Mullerian Cancer
    LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations
    1200.22.14 Boehringer Ingelheim Investigational Site
    Boston, Massachusetts
    Carcinoma, Non-Small-Cell Lung
    Young Women Diagnosed With Early Stage Ovarian Cancer: A Focus on Fertility Issues and Sexual Function
    Beth Israel Deaconess Medical Center

    Trial Locations
    Beth Israel Deaconess Medical Center
    Dana-Farber Cancer Institute
    Massachusetts General Hospital
    Ovarian Cancer
    Safety Study of LBH589 When Given in Combination With Bortezomib in Adult Patients With Multiple Myeloma
    Dana Farber Cancer Institute Clinical Research Coordinator
    Boston, Massachusetts 02115
    Multiple Myeloma
    Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders
    Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215
    AML, ALL, CLL, Myelodysplastic Syndrome, Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Multiple Myeloma, Aplastic Anemia, Myeloproliferative Disorder
    Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
    Beth Israel Deaconess Medical Center

    Trial Locations
    Beth Israel Deaconess Medical Center
    Dana-Farber Cancer Institute
    Massachusetts General Hospital
    Dana-Farber at Faulkner Hospital
    Breast Cancer, Carcinoma of the Breast
    The Active After Cancer Trial (AACT)
    Dana-Farber Cancer Institute
    Boston, Massachusetts 02115
    Breast Cancer, Colorectal Cancer
    Intermittent Letrozole Therapy in Postmenopausal Women With Metastatic Breast Cancer
    Dana-Farber Cancer Institute

    Trial Locations
    Dana-Farber Cancer Institute
    Massachusetts General Hospital
    Breast Cancer
    Selumetinib in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer
    Massachusetts General Hospital Cancer Center

    Trial Locations
    Massachusetts General Hospital Cancer Center
    Dana-Farber Cancer Institute
    Brigham and Women's Hospital
    Borderline Ovarian Surface Epithelial-stromal Tumor, Ovarian Serous Cystadenocarcinoma, Primary Peritoneal Cavity Cancer, Recurrent Borderline Ovarian Surface Epithelial-stromal Tumor
    S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
    Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute

    Trial Locations
    Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute
    Massachusetts General Hospital
    Dana-Farber/Brigham and Women's Cancer Center
    Leukemia
    Epratuzumab and Rituximab in Treating Patients With Previously Untreated Follicular Non-Hodgkin Lymphoma
    Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute

    Trial Locations
    Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
    Dana-Farber/Brigham and Women's Cancer Center
    Lymphoma
    Bortezomib and Lenalidomide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
    Brigham and Women's Hospital
    Boston, Massachusetts 02115
    Recurrent Mantle Cell Lymphoma
    The High-Dose Aldesleukin (IL-2) "Select" Trial for Patients With Metastatic Renal Cell Carcinoma
    Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215
    Metastatic Renal Cell Carcinoma
    Lapatinib in Treating Women With Ductal Carcinoma In Situ of the Breast
    Dana-Farber Cancer Institute
    Boston, Massachusetts 02115
    Breast Cancer, Ductal Breast Carcinoma in Situ
    Aromatase Inhibitors in Premenopausal Breast Cancer Patients With Chemotherapy-Induced Ovarian Failure
    Dana-Farber Cancer Center
    Boston, Massachusetts 02115
    Breast Cancer
    Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell Carcinoma
    Dana-Farber Cancer Institute
    Boston, Massachusetts 02115
    Renal Cell Carcinoma, Neoplasm Metastases